WORLD JOURNAL OF GASTROENTEROLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2025-03-31 ms7000001792667509 来自山西省

避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的

8 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2022-03-20 ms6000001874634655

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：胃肠道;肿瘤
经验分享：接收了

118 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2025-02-22 ms4000002102138234

这个杂志必须要英语润色才能投稿吗

12 0

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2024-09-25 493473315 来自安徽省

审稿速度:12.0 | 投稿命中率:5.0
经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志

56 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2024-12-07 ms2000001469182813 来自北京

精彩评论，需要您登录查看

39 13

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2024-11-19 SCIweichu1是V

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌
经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review

109 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2025-01-11 ms4000001827935840 来自福建省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。

22 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2025-01-12 ms5000002977722138 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肝癌
经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2024-12-24 lialunxi 来自广东省

偏重的研究方向：肝硬化
经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢

26 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2258480, encodeId=acc62258480d1, content=避雷吧，这个杂志送审也大概率被拒稿，因为必须要求审稿人评分A跟B，只要有C就不行，但其实C的含义是good，我三个审稿人，两个都是AB，只有一个是C，而且三个审稿人意见都很好，都是小修，最后让转投旗下另一个非SCI，挺离谱的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc88302593, createdName=ms7000001792667509, createdTime=Mon Mar 31 09:06:06 CST 2025, time=2025-03-31, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204377, encodeId=296c12043e7c1, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：胃肠道;肿瘤 经验分享：接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cb25583715, createdName=ms6000001874634655, createdTime=Sun Mar 20 17:11:34 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253121, encodeId=51f2225312123, content=这个杂志必须要英语润色才能投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=142c9446281, createdName=ms4000002102138234, createdTime=Sat Feb 22 22:43:50 CST 2025, time=2025-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227562, encodeId=44e7222e56227, content=审稿速度:12.0 | 投稿命中率:5.0 经验分享：6月份投稿，一直就是AI在寻找审稿人，添加了200多个，到了九月，终于找到一个，审稿人的意见也很搞笑，就是把我文章里自己写的不足之处复制了一遍，最后意见“小修”，本来以为有戏了，后来编辑部直接就给拒了，理由是他们接收的要求是三个审稿人至少达到ABB的评分以上（另外两位在哪？），编辑部对论文的评价也是一模一样的把我文中的不足之处复制了一遍，感觉审稿人和编辑部也根本就没有认真看文章，拒了以后让你改投他旗下的垃圾杂志。要是觉得我文章质量差大可以初审的时候直接拒掉，等了三个月的外审，期间发了无数邮件，一封也没有回，最后来这出，总之是个大坑杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98b24794178, createdName=493473315, createdTime=Wed Sep 25 08:50:54 CST 2024, time=2024-09-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2241218, encodeId=37eb2241218ea, content=这种状态是要被拒了嘛，求求解答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/640af84f17e143f993e59237fc1749de-w5VPsj4goXSW.png, type=image, width=1045, height=484)], authenticateStatus=null, createdAvatar=null, createdBy=9bd39563237, createdName=ms2000001469182813, createdTime=Sat Dec 07 12:46:20 CST 2024, time=2024-12-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237816, encodeId=ac83223e8165e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;胃肠道恶性肿瘤;肝癌 经验分享：历时一个月accept 中间约20天审稿和修改过程分享，有想投的可以聊聊，可以提供些帮助 24-11-12 Send Acceptance Letter to Author 24-11-09 Submit the Revised Manuscript 24-11-06 Author Accepts to Revise 24-10-30 Return the Manuscript to Author for Revision 24-10-30 Made First Decision by Executive Editor-in-Chief 24-10-30 Accept First Decision by Executive Editor-in-Chief 24-10-29 Send to Executive Editor-in-Chief for First Decision 24-10-29 Accept First Decision by Science Editor 24-10-29 Decline First Decision by Science Editor 24-10-12 Submit the Manuscript 24-10-12 Confirm the Receipt and Make General Assessment 24-10-12 Send to Science Editor for Manuscript Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/2f41f69ff42a4be5a4d50af463adba41-wSw7EsGPmncF.jpg, createdBy=3dca9541146, createdName=SCIweichu1是V, createdTime=Tue Nov 19 16:43:15 CST 2024, time=2024-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2247537, encodeId=72d2224e5374d, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4个月多接收，提交了很多材料，邀请了两百多个审稿人，整体下来还是比较规范和严谨的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aca46473105, createdName=ms4000001827935840, createdTime=Sat Jan 11 12:48:23 CST 2025, time=2025-01-11, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2247768, encodeId=36c5224e768e0, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：CB,BB，一值没有任何消息，比较担心，这样是不是被拒的概率很大呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722138, createdTime=Sun Jan 12 21:26:34 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2244654, encodeId=5dca224465469, content=偏重的研究方向：肝硬化 经验分享：WJG返修回，能再增加一个通讯作者么，这个会不会被杂志拒稿呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Tue Dec 24 13:59:40 CST 2024, time=2024-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=567000, encodeId=7c9956e0002c, content=投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=427, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54c92198239, createdName=120aafd2m69(暂无昵称), createdTime=Wed Feb 20 00:00:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

2019-02-20 120aafd2m69(暂无昵称)

投的综述目前两个审稿人意见回来了，都是小修，但1个科学性B语言B，另一个科学性C，语言B。会不会拒稿啊？

427 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务